Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination

Código QR

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination

Guardado en:

Detalles Bibliográficos
Autores principales:	Akihiro Matsubara, Mai Sakurai, Akimichi Morita
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/e10a8536133b482290391a71cd9896a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
por: Toshiyuki Sumi, et al.
Publicado: (2021)

Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres
por: Michael Cross, et al.
Publicado: (2021)

Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
por: Hannah E. Landsberg, MSN, MPH, et al.
Publicado: (2022)

Systemic drug-related intertriginous and flexural exanthema induced by the Pfizer-BioNTech COVID-19 vaccine: A report of 2 cases
por: Josephine Hai, BS, et al.
Publicado: (2021)

Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
por: Rami Alqassieh, et al.
Publicado: (2021)

Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia
por: Edrous Alamer, et al.
Publicado: (2021)

Minimal change nephrotic syndrome four days after the administration of Pfizer‐BioNTech COVID‐19 vaccine—a new side effect or coincidence?
por: Mohammed Abdulgayoom, et al.
Publicado: (2021)

Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine
por: Jessica Hanna, et al.
Publicado: (2021)

A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany
por: Rolf Schwarzer, et al.
Publicado: (2021)

A Young Man With Gravitational Urticarial Vasculitis
por: Ali Sadeghinia, et al.
Publicado: (2020)

RECURRENT AUTOIMMUNE HEMOLYTIC ANEMIA AFTER MRNA COVID-19 VACCINE (PFIZER-BIONTECH)
por: Fatma YILMAZ, et al.
Publicado: (2021)

Hyperkeratosis of the Nipple As a Neglected Dermatosis
por: Juan Jimenez-Cauhe, et al.
Publicado: (2019)

Facial discoid dermatosis: A cosmetically disfiguring and challenging condition to treat
por: S. Rahmatulla, et al.
Publicado: (2021)

Proton pump inhibitor-induced Sweet’s syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer
por: Philip R. Cohen
Publicado: (2015)

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
por: M.D. Maldonado, et al.
Publicado: (2021)

Dermatosis discoide facial, una entidad enigmática
por: L. Condal, et al.
Publicado: (2021)

Terra firma-forme dermatosis: A report of ten individuals with Duncan’s dirty dermatosis and literature review
por: Tanya Greywal, et al.
Publicado: (2015)

Acquired perforating dermatosis in the setting of hepatocellular carcinoma
por: Reinaldo Tovo Filho, MD, PhD, et al.
Publicado: (2021)

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
por: Yamato Nishiguchi, et al.
Publicado: (2021)

CHRONIC URTICARIAL IN CHILDHOOD. IMMUNE PATHOLOGY OF CHRONIC URTICARIAL IN CHILDREN (PART I)
por: N. A. Sinelnikova, et al.
Publicado: (2014)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Esther Saiag, et al.
Publicado: (2021)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Nicola Silvestris
Publicado: (2021)

Subcorneal pustular dermatosis as a cause of pityriasis amiantacea in a young child
por: Soo Ran Lee, MD, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
por: Timothy A. Bates, et al.
Publicado: (2021)

Eosinophilic dermatosis of hematologic malignancy mimicking varicella zoster infection: report in a woman with chronic lymphocytic leukemia and review of the literature
por: Omar Bari, et al.
Publicado: (2017)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
por: Krzysztof Lukaszuk, et al.
Publicado: (2021)

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
por: Benjamin Kahn, BA, et al.
Publicado: (2021)

BNT162b2 vaccine uptake and effectiveness in UK healthcare workers – a single centre cohort study
por: Tariq Azamgarhi, et al.
Publicado: (2021)

Dermatosis eritematoescamosas
por: Valdés A.,M. del Pilar
Publicado: (2005)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
por: Jia Ming Low, et al.
Publicado: (2021)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
por: Jing Zou, et al.
Publicado: (2021)

Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection
por: Elvira Baos, et al.
Publicado: (2022)

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
por: Delphina Gomes, et al.
Publicado: (2021)

A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine
por: Mira FS, et al.
Publicado: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Davide Ferrari, et al.
Publicado: (2021)

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Mohammad Shehab, et al.
Publicado: (2021)

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
por: Delphina Gomes, et al.
Publicado: (2021)

B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies
por: Federica Pulvirenti, et al.
Publicado: (2021)

Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
por: Shai Efrati, et al.
Publicado: (2021)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
por: Kazuki Takada, MD, PhD, et al.
Publicado: (2021)